CN103961431B - A kind of pharmaceutical composition that improves animal immunizing power - Google Patents
A kind of pharmaceutical composition that improves animal immunizing power Download PDFInfo
- Publication number
- CN103961431B CN103961431B CN201410196539.9A CN201410196539A CN103961431B CN 103961431 B CN103961431 B CN 103961431B CN 201410196539 A CN201410196539 A CN 201410196539A CN 103961431 B CN103961431 B CN 103961431B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- formulation
- parts
- animal
- fructus crataegi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active - Reinstated
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 230000003053 immunization Effects 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 33
- 235000014134 echinacea Nutrition 0.000 claims abstract description 24
- 241000132012 Atractylodes Species 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 238000009472 formulation Methods 0.000 claims abstract description 16
- 239000000273 veterinary drug Substances 0.000 claims abstract description 6
- 241000258180 Echinacea <Echinodermata> Species 0.000 claims abstract 3
- 239000000843 powder Substances 0.000 claims description 32
- 239000000463 material Substances 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000000295 complement effect Effects 0.000 claims description 7
- 238000000227 grinding Methods 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 238000011017 operating method Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 244000133098 Echinacea angustifolia Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 230000036039 immunity Effects 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 241000411851 herbal medicine Species 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 6
- 229960004397 cyclophosphamide Drugs 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000004459 forage Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- -1 antioxygenAgent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000035611 feeding Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WBDGLSGKTWAWHK-UHFFFAOYSA-N 2,3-dibutylbenzoic acid Chemical compound CCCCC1=CC=CC(C(O)=O)=C1CCCC WBDGLSGKTWAWHK-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 241001019773 Crataegus wilsonii Species 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 240000004530 Echinacea purpurea Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001579678 Panthea coenobita Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000001970 hydrokinetic effect Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of pharmaceutical composition that improves animal immunizing power, it is the formulation that the bulk drug that contains following weight proportion is prepared from: 5～8 parts of Echinacea roots, 2～4 parts of the bighead atractylodes rhizomes, 1～3 part of fructus crataegi cuneatae. Pharmaceutical composition of the present invention, compatibility is precise and appropriate, and each bulk drug is used in conjunction with has brought into play synergistic function, can significantly improve animal immunizing power and promote growth of animal, for veterinary drug provides new selection.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that improves animal immunizing power.
Background technology
Zoosis toxicity disease serious harm animal husbandry development, some Amphixenosis is also threatening the mankind strongHealth, comprises pig blue-ear disease, swine fever, aftosa etc., vaccine immunity failure, and Swinery immunity hypofunction,Swinery disease becomes increasingly complex, health to China's pig industry, fast, stable development caused seriousImpact. Since 2004, the Ministry of Agriculture has cancelled the use of antiviral class chemical drug at veterinary clinic, currentThere is no the application of antiviral class chemical classes medicine on veterinary clinic, therefore veterinary clinic is mainly by adoptingVeterinary drug carries out the prevention and control of viral disease. China has abundant herbal medicine resources advantage and sturdy grindingStudy carefully basis, comprising the research as the Radix Astragali, ginseng etc. with the herbal medicine that improves immunologic function. In realityIn the breeding process of border, the use of herbal medicine, taking the immunologic function that improves pig as object, can prevent and treat immunity and press downThe puzzlement of property disease processed, improves immune effect of vaccine, be the health that ensures China pig industry, fast, steadyThe primary selection of fixed development, these Chinese herbal medicines pass through to improve the defense function of body, thereby body is reachedThe effect of " healthy tendency internal memory, heresy can not be done ", thus play effectively indirect antivirus action, in suchMedicine, in improving animal body immunity, can improve the adaptive capacity of the body of animal, spleen benefiting and stimulating the appetite,Improve animal appetite, thereby promote the smooth growth of livestock and poultry.
Superfine communication technique is the new technology developing rapidly in the world over nearly 30 years, and it is to utilize machineryOr material particles is crushed to the even process of nanoscale micro mist of micron by hydrokinetic method. Chinese medicine warpAfter ultramicro grinding, can improve the sporoderm-broken rate of cell, increase the specific area of medicinal material, make effective ingredientStripping increases, and bioavilability improves, thereby can reduce clinical application amount. Therefore, this technology is used forIn Chinese medicine preparation, there is the drug solubility of raising, improve preparation mode of appearance, promote drug absorption, enhancingThe effects such as clinical efficacy.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition that improves animal immunizing power. Of the present invention anotherOne object is to provide the Preparation method and use of this pharmaceutical composition.
The invention provides a kind of pharmaceutical composition that improves animal immunizing power, it is to contain following weight to joinThe formulation that the bulk drug of ratio is prepared from:
5～8 parts of Echinacea roots, 2～4 parts of the bighead atractylodes rhizomes, 1～3 part of fructus crataegi cuneatae.
Further, it is the formulation that the bulk drug that contains following weight proportion is prepared from:
5 parts of Echinacea roots, 3 parts of the bighead atractylodes rhizomes, 2 parts of fructus crataegi cuneataes.
Further, it is the formulation being prepared from by the bulk drug of following weight proportion:
5～8 parts of Echinacea roots, 2～4 parts of the bighead atractylodes rhizomes, 1～3 part of fructus crataegi cuneatae.
Preferably, it is the formulation being prepared from by the bulk drug of following weight proportion:
5 parts of Echinacea roots, 3 parts of the bighead atractylodes rhizomes, 2 parts of fructus crataegi cuneataes.
Echinacea root origin is pale reddish brown in composite family (Asteraceae) Echinacea (EchinaceaMoench)The dry Root and Rootstock of Echinacea Echinaceapurpurea (L) Moench.
Fructus crataegi cuneatae derives from rose family may fructus crataegi cuneatae (CrataeguscuneataSieb.etZucc), the dry fruit of Central China hawthorn (C.wilsoniiSarg.) etc.
Wherein, it be by the medicinal powder of described bulk drug, water extract or/and ethanol extract is active component,Add the formulation that auxiliary material conventional on veterinary drug or complementary composition are prepared from.
Wherein, described formulation is through gastrointestinal absorption formulation. As powder, granule, oral liquid, tablet,Pill etc.
Water extract or be used as medicine with medicinal powder is all Chinese medicine tradition occupation modes, after water extraction, due to the dissolving of waterScope is wide, can, by most of active ingredient stripping, medicine is more easily absorbed by the body, and onset is faster,The form of medication such as such as decoction; Be used as medicine with former powder, the surface area of medicinal powder is larger, and being also conducive to has in medicinal materialThe absorption in vivo of effect composition, but medicinal material un-extracted, active ingredient still needs stripping in vivo to absorb again,The relative water extract of its onset is slower, but has also weakened the poison pair that in medicinal material, harmful components cause human body simultaneouslyReaction, is suitable for long-term taking, as former powder is prepared into the form of medication such as pill. At present at pharmacy procedureIn, ethanol extracts medicine as solvent, is also one of the most common extracting mode, and ethanol isSemi-polarity solvent, solubility property circle between polarity and non-polar solven, can dissolve water miscible someComposition, also can dissolve some compositions that non-polar solven dissolves, and conventionally replaces decocting with alcohol extract, fromAnd avoid the stripping of a large amount of invalid components, improve concentration and the extraction efficiency of active ingredient, but ethanolPrice is expensive compared with water, in the large production of modern pharmaceutical industry, in order to save production cost, conventionally still with waterIt is main decocting. In the situation that known compositions water extract of the present invention has physiologically active, various in order to adapt toDemand when producing and using, optionally prepared by water extraction, former powder, alcohol extracting or their combinationConcrete formulation.
Pharmaceutically acceptable auxiliary material of the present invention includes but are not limited to filler (diluent), lubricatedAgent (glidant or antitack agent), dispersant, wetting agent, adhesive, conditioning agent, solubilizer, antioxygenAgent, bacteriostatic agent, emulsifying agent, disintegrant etc. Adhesive comprises syrup, Arabic gum, gelatin, sorbAlcohol, tragacanth, cellulose and derivative thereof are (as microcrystalline cellulose, sodium carboxymethylcellulose, ethyl fibreDimension element or HPMC etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.; Fill outFill agent and comprise lactose, Icing Sugar, dextrin, starch and derivative thereof, cellulose and derivative thereof, inorganic calciumSalt (as calcium sulfate, calcium phosphate, calcium monohydrogen phosphate, precipitated calcium carbonate etc.), sorbierite or glycine etc.; ProfitLubrication prescription comprises superfine silica gel powder, dolomol, talcum powder, aluminium hydroxide, boric acid, hydrogenated vegetable oil, poly-Ethylene glycol etc.; Disintegrant comprise starch and derivative thereof (as sodium carboxymethyl starch, Explotab,Pregelatinized starch, modified starch, hydroxypropul starch, cornstarch etc.), polyvinylpyrrolidone or crystalliteCellulose etc.; Wetting agent comprises lauryl sodium sulfate, water or alcohol etc.; Antioxidant packages containing sodium sulfite,Sodium hydrogensulfite, sodium pyrosulfite, dibutyl benzoic acid etc.; Bacteriostatic agent comprise 0.5% phenol, 0.3% cresols,0.5% anesin etc.; Conditioning agent comprises hydrochloric acid, citric acid, potassium hydroxide (sodium), sodium citrateAnd buffer (comprising phosphoric acid dioxy sodium and sodium hydrogen phosphate) etc.; Emulsifier package contains Tween-80, does not haveAcid sorb is smooth, pluronic gram F-68, lecithin, Fabaceous Lecithin etc.; Solubilizer comprise Tween-80, bile,Glycerine etc.
Described pharmaceutically acceptable complementary composition, it has certain physiologically active, but the adding of this compositionEnter can not change the leading position of aforementioned pharmaceutical compositions in disease treatment process, and only performance is auxiliaryEffect, these auxiliary effects are only the utilizations to this composition known activity, are usual auxiliary of field of medicamentsHelp therapeutic modality. If above-mentioned complementary composition and pharmaceutical composition of the present invention are used in conjunction with, still should belong toIn the scope of protection of the invention.
Certainly, pharmaceutical composition of the present invention, also comprises and the extract of above-mentioned each medicinal material passes through said ratioThe composition that each extract compatibility that conversion obtains with recovery rate uses.
The present invention also provides the preparation method of aforementioned pharmaceutical compositions, and it comprises following operating procedure:
(1) by proportioning weighting raw materials;
(2) after bulk drug is pulverized, mix, add auxiliary material conventional on veterinary drug or the preparation of complementary compositionBecome formulation.
Further, described pulverizing is ultramicro grinding.
The present invention also provides aforementioned pharmaceutical compositions to improve animal immunizing power in preparation, promote growth of animalMedicine in purposes.
Further, described animal is mammal or bird, as is chicken, duck, pig, ox, sheep or mouse.
Pharmaceutical composition of the present invention, compatibility is precise and appropriate, and each bulk drug is used in conjunction with has brought into play synergistic function,Can significantly improve animal immunizing power and promote growth of animal, for veterinary drug provides new selection.
Detailed description of the invention
The preparation of embodiment 1 present composition
Echinacea root 500g bighead atractylodes rhizome 300g fructus crataegi cuneatae 200g
(1) get Rhizoma Atractylodis Macrocephalae, add 20 times of water gagings, take extraction by steam distillation volatile oil, collectVolatile oil is for subsequent use, and it is 1.10～1.12 medicinal extract that extract is evaporated to density, the dry (spray of sprayingMist drying condition: EAT: 150～170 DEG C, leaving air temp: 90～100 DEG C) make bighead atractylodes rhizome medicinal extractPowder.
(2) get Echinacea root, fructus crataegi cuneatae two taste medicinal materials, it is below 5% that forced air drying makes water content, normalRule were pulverized No. five sieves (80 order), obtained medicinal material fine powder mixture, mixture is put in micronizer,Under the cryogenic conditions of-20 DEG C, ultramicro grinding more than 20 minutes, is crossed 300 mesh sieves, obtains particle diameter and is less than 50 μ mUltramicro-powder.
(3) after Ultramicro-powder, bighead atractylodes rhizome extract powder, volatile oil are mixed, packing, sterilizing, carriedThe herbal medicine ultra micro powder of high immunity of livestock.
The preparation of embodiment 2 present compositions
Echinacea root 800g bighead atractylodes rhizome 200g fructus crataegi cuneatae 100g
(1) get Rhizoma Atractylodis Macrocephalae, add 15 times of water gagings, take extraction by steam distillation volatile oil, collectVolatile oil is for subsequent use;
(2) bighead atractylodes rhizome dregs of a decoction and fructus crataegi cuneatae medicinal material are added to 10 times of water gagings extractions three times, each 1 hour, closeAnd decocting liquid, to filter, it is 1.10～1.12 medicinal extract that filtrate decompression is concentrated into density, the dry (spraying of sprayingDrying condition: EAT: 150～170 DEG C, leaving air temp: 90～100 DEG C) make extract powder.
(3) get Echinacea root herb, it is below 5% that forced air drying makes water content, and routine was pulverized No. fiveSieve (80 order), obtains medicinal material fine powder, medicinal material fine powder is put in micronizer, in the cryogenic conditions of-20 DEG CLower ultramicro grinding more than 20 minutes, is crossed 300 mesh sieves, obtains the Ultramicro-powder that particle diameter is less than 50 μ m.
(4) after Ultramicro-powder, extract powder, volatile oil are mixed, packing, sterilizing, poultry is improvedThe herbal medicine ultra micro powder of immunity of fowl.
The preparation of embodiment 3 present compositions
Echinacea root 500g bighead atractylodes rhizome 300g fructus crataegi cuneatae 200g
By after above-mentioned medicinal material drying, coarse crushing, then through ultramicro grinding, cross 300 mesh sieves, obtain particle diameter and be less than 50The Ultramicro-powder of μ m, obtains ultra micro powder.
The preparation of embodiment 4 present compositions
Echinacea root 500g bighead atractylodes rhizome 400g fructus crataegi cuneatae 300g
Above-mentioned medicinal material, boiling 3 times decocts 2～3 hours at every turn, merges decocting liquid, concentrated, systemStandby conventional herbal medicine formulation.
Illustrate beneficial effect of the present invention by test example below. In following each test example, each Chinese medicine experimentGroup dosage is all in crude drug amount. Present composition ultra micro is loose to be prepared by embodiment 3.
The drug activity research of test example 1 pharmaceutical composition of the present invention
1 animal grouping
180 of kunming mices, are divided into 6 groups at random;
Normal group: only gavage physiological saline 0.5ml/, continuously 7d;
Endoxan model group: only gavage physiological saline 0.5ml/, 7d continuously, in gavaging the 3rd day,Intraperitoneal injection of cyclophosphamide 80mg/kg body weight, continuously 2d;
Echinacea root+endoxan group: gavage Echinacea root simple Ultramicro-powder suspension 1000mg/kgBody weight, 7d continuously, in gavaging the 3rd day, intraperitoneal injection of cyclophosphamide 80mg/kg body weight, continuously 2d;
The bighead atractylodes rhizome+endoxan group: gavage bighead atractylodes rhizome simple Ultramicro-powder suspension 1000mg/kg body weight, continuously7d, in gavaging the 3rd day, intraperitoneal injection of cyclophosphamide 80mg/kg body weight, continuously 2d;
Fructus crataegi cuneatae+endoxan group: gavage fructus crataegi cuneatae simple Ultramicro-powder suspension 1000mg/kg body weight,7d continuously, in gavaging the 3rd day, intraperitoneal injection of cyclophosphamide 80mg/kg body weight, continuously 2d;
Fall apart+endoxan group of present composition ultra micro: gavage the loose 1000mg/kg body weight of Chinese medicine ultra micro, connectContinuous 7d, in gavaging the 3rd day, intraperitoneal injection of cyclophosphamide 80mg/kg body weight, continuously 2d.
Wherein, the superfine grinding method of single medicinal material is identical with the present composition.
The mensuration of 2 mouse immune organ indexes
Administration finishes rear title Mouse Weight, and mouse is put to death in cervical vertebra dislocation, claims its spleen, thymus gland weight in wet base, meterCalculate spleen index and thymus index:
Spleen index=spleen weight (mg)/body weight (g)
Thymus index=thymic weight (mg)/body weight (g)
The mensuration of 3 mononuclear-macrophage phagocytic functions (carbon particle clearance speed)
1h after the administration of each group last, weighs, and each mouse is all injected and printed by tail vein by 0.1ml/10g dosageDegree prepared Chinese ink (with physiological saline press 1:5 dilute), after injection respectively at 1min (t1) and 5min (t2) from mouseEye socket veniplex is got blood 20 μ l, is dissolved in 2.0ml concentration 0.1%Na2CO3In solution, shake up, place 20minAfter in 680nm place survey its absorbance (A), with concentration 0.1%Na2CO3Solution is made blank, willMouse is got liver and spleen after putting to death, and weighs after blotting bloodstain with filter paper, calculates and cleans up index according to formulaIndex α value is cleaned up in K value and correction. Computing formula:
K＝(logA1-logA2)/(t2-t1)
α＝K1/3х body weight/(liver weight+spleen weight)
The detection of 4 mice serum hemolysins
Administration the 3rd day, every mouse lumbar injection 2%SRBC0.2ml sensitization, and continue administration. After sensitization4 days after last administration 90min get eyeball of mouse blood, leave standstill 1h, the centrifugal 10min of 2000r/min, getsUpper serum 20 μ l, with 500 times of NS dilutions, get this serum sample 1ml as complement, and 37 DEG C of temperature are bathed 1h,Reaction finishes, reaction tube moved in ice bath immediately, and with cessation reaction, with the centrifugal 10min of 2000r/min,Get 1ml supernatant and be contained in containing the test tube of 3ml Dou Shi reagent and shake up, survey it in 540nm after placing 10minAbsorbance (A). Calculate the HD50 value (HC of mouse50)。
Sample HC50=(absorbance when absorbance/SRBC HD50 of sample) х extension rate
5 data processings
Utilize SPSS13.0 to carry out statistical analysis, significance analysis adopts one-way analysis of variance and multiple ratio.
6 results and analysis
Table 1 Chinese medicine ultra micro is loose to mouse immune activity influence result of the test
Note: a), with normal group ratio, P < 0.05;
B), with model group ratio, P < 0.05;
As seen from the results in Table 1, after normal mouse intraperitoneal injection of cyclophosphamide, can significantly reduce mouse spleenWith the weight of thymus gland, significant difference compared with Normal group (P < 0.05), illustrates that immunosupress model buildsStand successfully; The each indicator and model group of fructus crataegi cuneatae group is compared basic indifference, illustrates that fructus crataegi cuneatae immunity strengthens workA little less than, possesses hardly this effect; Bighead atractylodes rhizome group thymus index, clean up index phagocytic index, half is moltenBlood value is significantly higher than model group (P < 0.05), but also there are differences compared with normal group, and its immunity strengthens to be doneWith being weaker than Echinacea root group; By contrast, loose obviously to improve immunosupress little for present composition ultra microMouse index and spleen index, thymus index, HD50 value, phagocytic index, clean up the indexs such as index, with ring phosphorusAcid amides group is compared significant difference (P < 0.05), and mouse indices returns to normal level substantially, and curative effect is excellentIn simple Ultramicro-powder groups such as Echinacea roots, proving present composition ultra micro, loose to improve immunosupress littleThe immunocompetence of mouse, can resist the immunosupress that endoxan causes, curative effect is better than each simple in prescriptionUltramicro-powder group, illustrates that medicinal material compatibility of the present invention brought into play synergistic function.
Test example 2 clinical verification tests
1 test grouping and processing
Choose 200 of 1 basically identical age in days broiler chicks of Leshan one plant's health, body weight, divide at randomBe 5 groups, 40 every group. 1 group is blank group (not administration); 2 groups is that bighead atractylodes rhizome group is (by every dayThe amount spice of forage volume 1% is given and bighead atractylodes rhizome simple Ultramicro-powder; 3 groups is that fructus crataegi cuneatae group is (by forage volume every day1% amount spice is given and fructus crataegi cuneatae simple Ultramicro-powder; 4 groups is that Echinacea root group is (by forage volume 1% every dayAmount spice give and Echinacea root simple Ultramicro-powder; 5 groups is that composition administration group is (by forage volume every day1% amount is given and the invention described above composition ultra micro powder). Experimental period, is: 5～42 ages in days, and to enter young working asDay is as 1 age in days.
2 basal diet composition and trophic level
According to the fast large-scale feeding of broiler standard preparation of China, daily ration is once got all the ready.
3 feedings and managements and immunity
Test chicken all adopts bilayer to raise in cages, free choice feeding and drinking-water, and hen house keeps hygienically clean, and ventilatesWell.
4 test indexs and method
Respectively at before test, when 42 age in days by only weighing on an empty stomach, weigh broiler fodder consumption every day, systemMeter is respectively organized average weight, daily gain, feed consumption rate, feedstuff-meat ratio etc.
5 result of the tests and analysis
The comparison of table 2 result of the test
As shown in Table 2, except fructus crataegi cuneatae, each administration group all has the effect of obvious promotion growth of meat chicken,Chicken weight gain on the 42nd is all apparently higher than blank group, composition administration group growth-promoting effect optimum; FromFeedstuff-meat ratio sees, except fructus crataegi cuneatae, each administration group feedstuff-meat ratio is all starkly lower than blank group, of the present invention groupCompound administration group curative effect is more remarkable, and be better than Echinacea very with bighead atractylodes rhizome simple administration group, and fructus crataegi cuneataeThe growth promoting function of group is the poorest. Prove that this pharmaceutical composition is in improving animal body immunity, alsoHave significant growth promoting function, curative effect is better than each simple, has brought into play synergistic function, is this medicineClinical practice reference is provided.
Claims (8)
1. a pharmaceutical composition that improves animal immunizing power, is characterized in that: it is to be joined by following weightThe formulation that the bulk drug of ratio is prepared from:
5～8 parts of Echinacea roots, 2～4 parts of the bighead atractylodes rhizomes, 1～3 part of fructus crataegi cuneatae.
2. pharmaceutical composition according to claim 1, is characterized in that: it is to be joined by following weightThe formulation that the bulk drug of ratio is prepared from:
5 parts of Echinacea roots, 3 parts of the bighead atractylodes rhizomes, 2 parts of fructus crataegi cuneataes.
3. pharmaceutical composition according to claim 1 and 2, is characterized in that: it is by described formerThe medicinal powder, water extract of material medicine is or/and ethanol extract is active component, add auxiliary material conventional on veterinary drug orThe formulation that complementary composition is prepared from.
4. pharmaceutical composition according to claim 3, is characterized in that: described formulation is through stomach and intestineRoad absorption type.
5. the preparation method of pharmaceutical composition described in claim 1～4 any one, is characterized in that:It comprises following operating procedure:
(1) by proportioning weighting raw materials;
(2) after bulk drug is pulverized, mix, add auxiliary material conventional on veterinary drug or the preparation of complementary compositionBecome formulation.
6. preparation method according to claim 5, is characterized in that: described pulverizing is ultramicro grinding.
7. described in claim 1～4 any one, pharmaceutical composition improves animal immunizing power, short in preparationEnter the purposes in the medicine of growth of animal.
8. purposes according to claim 7, is characterized in that: described animal is mammal or fowlClass.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410196539.9A CN103961431B (en) | 2014-05-12 | 2014-05-12 | A kind of pharmaceutical composition that improves animal immunizing power |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410196539.9A CN103961431B (en) | 2014-05-12 | 2014-05-12 | A kind of pharmaceutical composition that improves animal immunizing power |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103961431A CN103961431A (en) | 2014-08-06 |
| CN103961431B true CN103961431B (en) | 2016-05-04 |
Family
ID=51231752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410196539.9A Active - Reinstated CN103961431B (en) | 2014-05-12 | 2014-05-12 | A kind of pharmaceutical composition that improves animal immunizing power |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103961431B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106490325A (en) * | 2016-11-07 | 2017-03-15 | 成都乾坤动物药业股份有限公司 | A kind of Chinese veterinary medicinal composition for promoting growth of animal |
| CN106509355A (en) * | 2016-11-07 | 2017-03-22 | 成都乾坤动物药业股份有限公司 | Traditional Chinese veterinary medicinal composition for improving production performance of livestock and poultry |
-
2014
- 2014-05-12 CN CN201410196539.9A patent/CN103961431B/en active Active - Reinstated
Non-Patent Citations (2)
| Title |
|---|
| 白术、微米白术及白术多糖对断奶仔猪生长性能和免疫功能的影响;赵燕飞等;《中国畜牧杂志》;20121231;第48卷(第13期);第56-59页 * |
| 紫雏菊及其提取物在国内的研究进展与应用;要瑞丽;《中国动物保健》;20131231;第15卷(第9期);第19-21页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103961431A (en) | 2014-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN105919136A (en) | Nutrition supplement composition with fatigue resisting and immunity improving effects and preparation and preparation method thereof | |
| CN104000197B (en) | A kind of health products or pharmaceutical composition and its production and use of fatigue-relieving | |
| CN103405536A (en) | Chinese herbal veterinary drug used for treating diarrhoea and preparation method thereof | |
| CN105878765A (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN103961431B (en) | A kind of pharmaceutical composition that improves animal immunizing power | |
| CN104000944B (en) | A kind of health products or pharmaceutical composition and its production and use with warming kidney to invigorate yang | |
| CN103859406B (en) | Immunity-improving colla corii asini and jujube capsule | |
| CN102247570B (en) | Traditional Chinese medicine composition for treating cow ketosis | |
| CN102106965A (en) | Composition for treating acute injury of soft tissue and application thereof | |
| KR102416513B1 (en) | Composition for preventing and improving pet constipation and manufacturing method thereof | |
| CN103520316B (en) | Traditional Chinese medicine for preventing and treating livestock and poultry diarrhoea and preparation method | |
| CN105535094A (en) | Traditional Chinese medicine composition for facilitating beast, bird and fish production performance | |
| CN103989750B (en) | A pharmaceutical composition boosting animal immunity and a preparation method thereof | |
| KR100673266B1 (en) | A growth-promoting composition | |
| CN102836334B (en) | Veterinary Chinese medicinal preparation for replenishing qi to invigorate spleen | |
| CN105395702A (en) | Composition with hangover alleviating, liver protecting and anti-fatigue efficacy and application thereof | |
| CN103948662A (en) | Medicinal composition for strengthening animal immunity | |
| CN101524479B (en) | Medicine for curing avian infectious bronchitis | |
| CN102379920A (en) | Veterinary antiviral and antifebrile drug composition | |
| CN102614253B (en) | Composition for nourishing and protecting liver and application of composition | |
| WO2016041462A1 (en) | Pharmaceutical composition for treating snoring, preparation method therefor and use thereof | |
| CN103933097A (en) | Pharmaceutical composition for strengthening animal immunity and preparation method thereof | |
| CN105770054A (en) | Pharmaceutical composition for preventing and treating chicken coccocidiosis, additive and feed | |
| CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 611130 Wenjiang City, Chengdu Province, Chengdu cross strait science and Technology Industrial Park Road, No. 259 Jin Fu Road, No. Patentee after: Chengdu Qiankun animal pharmaceutical Limited by Share Ltd Address before: 611130 Wenjiang, Chengdu, Chengdu cross strait science and Technology Industrial Development Zone, Jin Fu Road, Sichuan Patentee before: Chengdu Qiankun Animal Pharmaceutical Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160504 Termination date: 20190512 |
|
| RR01 | Reinstatement of patent right | ||
| RR01 | Reinstatement of patent right |
Former decision: termination of patent right due to unpaid annual fee Former decision publication date: 20200501 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210308 Address after: 610000 Jinfu Road, Cross-Strait Science and Technology Industrial Development Park, Wenjiang District, Chengdu City, Sichuan Province Patentee after: CHENGDU QIANKUN VETERINARY PHARMACEUTICAL Co.,Ltd. Patentee after: SICHUAN QIANKUN BIOTECHNOLOGY Co.,Ltd. Address before: 611130 no.259 Jinfu Road, Chengdu cross strait science and Technology Industrial Development Park, Wenjiang District, Chengdu City, Sichuan Province Patentee before: CHENGDU QIANKUN VETERINARY PHARMACEUTICAL Co.,Ltd. |